Canaccord Genuity analyst Richard Close has maintained a Buy rating on LifeStance Health Group while raising the price target to $13 from the previous $11. The adjustment signals a more optimistic outlook for the company's stock performance.

The revised target price suggests potential upside from current levels, driven by the analyst's positive assessment of LifeStance's operational strength and market position. The company continues to focus on expanding its behavioral health services across the United States.

Key Rating Details

The Buy rating indicates that the analyst expects LifeStance Health Group to outperform the broader market. Investors will likely monitor the company's quarterly results for signs of progress toward the new price target.

LifeStance Health Group, Inc. will issue its second quarter 2026 earnings release before the market opens on August 6, 2026. The company, one of the nation’s largest providers of outpatient mental healthcare, will host a live earnings conference call to discuss the results at 8:30 a.m. Eastern Time on the same day.

Conference Call Details

To participate in the call, domestic participants can dial 1-800-715-9871, while international participants can dial 1-646-307-1963. The conference ID required for participation is 6776851. Alternatively, participants can ask to be joined into the LifeStance call.

Webcast and Replay

A real-time audio webcast of the conference call will be accessible via the Events and Presentations section of the LifeStance Investor Relations website. Related materials will be posted on the website prior to the call. A replay of the webcast will be available after the conclusion of the conference call on the same platform.

About LifeStance Health Group

Founded in 2017, LifeStance provides virtual and in-person outpatient mental healthcare for children, adolescents, and adults. The company operates across 33 states with more than 550 centers, employing over 8,300 psychiatrists, advanced practice nurses, psychologists, and therapists.